Michael J. Tomsicek

2018 - CRISPR Therapeutics AG

In 2018, Michael J. Tomsicek earned a total compensation of $2.3M as Chief Financial Officer at CRISPR Therapeutics AG, a 4% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$209,760
Option Awards$1,653,972
Salary$380,000
Other$9,625
Total$2,253,357

Tomsicek received $1.7M in option awards, accounting for 73% of the total pay in 2018.

Tomsicek also received $209.8K in non-equity incentive plan, $380K in salary and $9.6K in other compensation.

Rankings

In 2018, Michael J. Tomsicek's compensation ranked 5,120th out of 14,244 executives tracked by ExecPay. In other words, Tomsicek earned more than 64.1% of executives.

ClassificationRankingPercentile
All
5,120
out of 14,244
64th
Division
Manufacturing
1,930
out of 5,759
67th
Major group
Chemicals And Allied Products
706
out of 2,122
67th
Industry group
Drugs
590
out of 1,811
67th
Industry
Biological Products, Except Diagnostic Substances
119
out of 339
65th
Source: SEC filing on April 30, 2019.

Tomsicek's colleagues

We found four more compensation records of executives who worked with Michael J. Tomsicek at CRISPR Therapeutics AG in 2018.

2018

Samarth Kulkarni

CRISPR Therapeutics AG

Chief Executive Officer

2018

Tony Ho

CRISPR Therapeutics AG

EVP, Research and Development

2018

James Kasinger

CRISPR Therapeutics AG

General Counsel

2018

Rodger Novak

CRISPR Therapeutics AG

President

News

In-depth

You may also like